These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 36293281

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J.
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK, Pyke C, von Herrath MG, Hasselby JP, Pedersen L, Mortensen PG, Knudsen LB, Coppieters K.
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Protection of exendin-4 analogue in early experimental diabetic retinopathy.
    Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W.
    Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):699-706. PubMed ID: 19084986
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 11. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma.
    Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL.
    Br J Ophthalmol; 2023 Feb 29; 107(2):215-220. PubMed ID: 34413054
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA.
    J Diabetes; 2019 Dec 29; 11(12):938-948. PubMed ID: 31318152
    [Abstract] [Full Text] [Related]

  • 14. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
    Hernández C, Bogdanov P, Corraliza L, García-Ramírez M, Solà-Adell C, Arranz JA, Arroba AI, Valverde AM, Simó R.
    Diabetes; 2016 Jan 29; 65(1):172-87. PubMed ID: 26384381
    [Abstract] [Full Text] [Related]

  • 15. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
    Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, Assi E, Seelam AJ, El Essawy B, Jang J, Loretelli C, D'Addio F, Berra C, Ben Nasr M, Zuccotti G, Fiorina P.
    Pharmacol Res; 2022 Aug 29; 182():106320. PubMed ID: 35738455
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.
    Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y.
    Front Endocrinol (Lausanne); 2021 Aug 29; 12():721135. PubMed ID: 34497589
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.